CymaBay price target raised to $13 from $10 at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on CymaBay to $13 from $10 and keeps an Overweight rating on the shares. Cantor Fitzgerald maintained CymaBay as a top pick, and believes there is more value to be unlocked heading into the Phase 3 primary biliary cholangitis data from seladelpar, expected in 3Q23, the analyst tells investors in a research note.